- Report
- March 2025
- 200 Pages
Global
From €4304EUR$4,490USD£3,597GBP
- Report
- September 2024
- 175 Pages
Global
From €4793EUR$5,000USD£4,005GBP
- Report
- August 2024
- 175 Pages
Global
From €4793EUR$5,000USD£4,005GBP
- Report
- August 2024
- 150 Pages
Global
From €2674EUR$2,789USD£2,234GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3106EUR$3,240USD£2,595GBP
€3451EUR$3,600USD£2,884GBP
- Report
- July 2023
- 220 Pages
Global
From €1908EUR$1,990USD£1,594GBP
- Report
- January 2024
- 189 Pages
Global
From €7190EUR$7,500USD£6,008GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1438EUR$1,500USD£1,202GBP
- Report
- April 2024
- 30 Pages
Global
From €3116EUR$3,250USD£2,603GBP
- Report
- March 2024
- 200 Pages
Global
From €3978EUR$4,150USD£3,324GBP
- Report
- July 2024
- 70 Pages
Brazil
From €4554EUR$4,750USD£3,805GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4554EUR$4,750USD£3,805GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4554EUR$4,750USD£3,805GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4554EUR$4,750USD£3,805GBP
- Report
- February 2024
- 70 Pages
India
From €4554EUR$4,750USD£3,805GBP
- Report
- February 2024
- 150 Pages
Global
From €4554EUR$4,750USD£3,805GBP
- Report
- February 2024
- 90 Pages
Africa, Middle East
From €4554EUR$4,750USD£3,805GBP
- Report
- February 2024
- 70 Pages
Japan
From €4554EUR$4,750USD£3,805GBP
- Report
- February 2024
- 70 Pages
Italy
From €4554EUR$4,750USD£3,805GBP
- Report
- February 2024
- 70 Pages
India
From €4554EUR$4,750USD£3,805GBP

Dapagliflozin is a drug used to treat endocrine and metabolic disorders. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose in the kidneys, leading to increased excretion of glucose in the urine. This helps to reduce blood sugar levels in people with type 2 diabetes. Dapagliflozin is also used to reduce the risk of cardiovascular events in adults with type 2 diabetes.
Dapagliflozin is available in both tablet and oral solution form and is typically taken once daily. Common side effects include urinary tract infections, increased urination, and genital yeast infections.
The Dapagliflozin market is highly competitive, with several major pharmaceutical companies offering the drug. These include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Novo Nordisk. Show Less Read more